Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
Pharmabiz9h
ME Therapeutics to begin testing of first mRNA formulations from NanoVation Therapeutics collaboration
ME Therapeutics to begin testing of first mRNA formulations from NanoVation Therapeutics collaboration: Vancouver, British Columbia Friday, September 20, 2024, 14:00 Hrs [IST] ME ...
Vancouver21h
Vancouver biotech inks $800M partnership with Novo Nordisk
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
BCBusiness21h
UBC’s NanoVation Therapeutics inks US$600 million deal with Novo Nordisk
The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...
GlobalData on MSN22h
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.